Skip to main content
. 2024 Jan 3;19:6. doi: 10.1186/s13019-023-02476-y

Table 2.

Therapeutic effects of CBD and the ECS on vascular disease

Disease Sample Research Target Summary outcome Reference
CAD Human; Subjects of white, black, and Asian ancestry (n = 2667); FAAH cDNA polymorphism FAAH 385 A/A missense polymorphism is a risk factor for overweight/obesity, which are also risk factors for CAD. [45]
Human; Individuals from the German MI family study (n = 1968); CNR2 (encoding CB2) variations Common CNR2 variations confer no susceptibility to CAD. [46]
Human; Overweight/obese patients (n = 6897); Rimonabant (CB1 antagonist) In overweight/obese patients, rimonabant induced weight loss and significant improvements in multiple cardiometabolic risk factors. [47]
Mouse; ApoE-/- mice (n = 48); Exercise and rimonabant treatments Both exercise and rimonabant treatments induced plaque regression and promoted plaque stability. [48]
Mouse; type I diabetic cardiomyopathy mouse model; CBD CBD could have a high therapeutic potential in the management of cardiovascular disorders by attenuating oxidative/nitrative stress, inflammation, cell death, and fibrosis. [53]
Cell; Mouse microglial cells; CBD CBD exerted its anti-inflammatory effects on microglia via its intrinsic antioxidant properties, which are amplified by the inhibition of glucose-dependent NADPH synthesis. [50]
Cell; BV-2 microglial cells; CBD CBD affected genes involved in the regulation of stress response and inflammation, mainly via the Nrf2/Hmox1 axis and the Nrf2/ATF4-Trib3 pathway. [51]
Hypertension Human; Healthy participants (n = 12); CBD and TurboCBD™ TurboCBD™ 90 mg was associated with a slight reduction in BP. [64]
Human; Healthy male participants (n = 26); CBD CBD reduced BP at rest after a single dose, but the effect was lost after seven days of treatment. [66]
Human; Healthy male participants (n = 9); CBD Acute administration of CBD reduces resting BP and stress-induced hypertension. [71]
Rat; Spontaneously and deoxycorticosterone hypertensive rats; CBD Chronic CBD administration did not exert an antihypertensive effect in primary and deoxycorticosterone hypertension model. [65]
Rat; Male Wistar rats; CBD CBD showed anxiolytic-like properties similar to those of diazepam in a rat model of conditioned fear to context. [70]
DRVD Human; Noninsulin-treated type 2 diabetes patients (n = 62); CBD CBD decreased insulin resistance and increased glucose-dependent insulinotropic peptide levels. [73]
Rat; Zucker D\diabetic fatty rats CBD Increased circulating endocannabinoids could alter the vascular function in type 2 diabetes, possibly due to endothelium-dependent vasorelaxation improvement. [77]
Cell; Human coronary artery endothelial cell; CBD CBD could have significant therapeutic benefits against diabetic complications and atherosclerosis. [74]
Cell; Type I diabetic cardiomyopathy mouse model; CBD CBD could have a high therapeutic potential in the treatment of cardiovascular disorders, by attenuating oxidative/nitrative stress, inflammation, cell death, and fibrosis. [53]
I/R injury Rat; Ischemic rat hearts model; CBD CBD exerted a substantial in vivo cardioprotective effect. [78]
Rat; Male rats; CBD CBD showed a therapeutic effect against I/R injury-induced arrhythmias via the activation of adenosine A1 receptor. [79]
Rat; CBD CBD demonstrated a therapeutic effect against CI, possibly by diminishing TNFR1/NF-κB-induced neurotoxicity. [81]
Rat; Neonatal Wistar rats; CBD CBD administration after middle cerebral artery occlusion led to long-term functional recovery, neuronal loss and astrogliosis reduction, and modulation of apoptosis, metabolic derangement, excitotoxicity and neuro-inflammation. [82]
Piglet; Hypoxic-ischemic newborn piglets CBD The combined effect of hypothermia and CBD on excitotoxicity, inflammation, oxidative stress, and cell damage is greater than the effects of either hypothermia or CBD alone. [83]
Piglet; Hypoxic-ischemic newborn piglets CBD CBD administration after hypoxia-ischemia in piglets showed neuroprotective effects. [84]

ApoE-/-, apolipoprotein E-deficient; Abn-CBD, abnormal cannabidiol; BP, blood pressure; CAD, coronary artery disease; CI, cerebral infarction; DRVD, diabetes-related vascular disease; ECS, endocannabinoid system; FAAH, fatty acid amide hydrolase; GPR18, G protein-coupled receptor; I/R injury, ischemia-reperfusion injury; NADPH, nicotinamide adenine dinucleotide phosphate; MI, myocardial infarction